Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2021 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -29.33m | 8.76% |
| EBITDA | -28.12m | 3.17% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €0 |
| Dividends | No |
Beta | 1.15 |
P/E ratio | -0.07 |
PEG ratio | 0.00 |
P/B ratio | 0.13 |
P/S ratio | 0.00 |
Company profile
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
| Name | Allena Pharmaceuticals |
| CEO | Louis Brenner |
| Headquarters | Newton,
ma USA |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 02/11/2017 |
| Employees | 12 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ALNA |
